Beranda › Kanker Paru Non-Sel Kecil › Tennessee › Nashville
Uji klinis Kanker Paru Non-Sel Kecil di Nashville, TN
97 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Nashville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- SCRI Oncology Partners /ID# 270162, Nashville
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 2/3
- SCRI Oncology Partners /ID# 276959, Nashville
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Menerima pesertaFase 3
- Elliston Place Medical Oncology & Hematology ( Site 0215), Nashville
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Menerima pesertaFase 2/3
- Tennessee Oncology, Nashville
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Menerima pesertaFase 3
- Tennessee Oncology - Nashville - St. Thomas West Clinic, Nashville
- Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) - Corporate, Nashville
- Tennessee Oncology - Franklin Clinic, Franklin · 17 mi jauhnya
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #3, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Menerima pesertaFase 3
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Menerima pesertaFase 3
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- PHN-012-001 Site, Nashville
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Menerima pesertaFase 1
- Research Site, Nashville
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Menerima pesertaFase 3
- SCRI Oncology Partners - Tennessee, Nashville
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic, Nashville
- dan 2 lainnya
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Menerima pesertaStudi observasional
- Vanderbilt University Medical Center, Nashville
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Menerima pesertaFase 3
- Sarah Cannon Research Institute, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology, Nashville
- Tennessee Oncology, PLLC - Saint Thomas West, Nashville
- dan 3 lainnya
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Menerima pesertaFase 1
- Research Site, Nashville
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Sarah Cannon Research Institute, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Menerima pesertaFase 1/2
- Vanderbilt University Medical Center, Nashville
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Research Site, Nashville
- Research Site, Nashville
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Menerima pesertaFase 3
- SCRI Oncology Partners, Nashville
- Local Institution - 0697, Nashville
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Menerima pesertaFase 2/3
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Menerima pesertaFase 2/3
- Tennessee Oncology, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institue, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon - Tennessee Oncology, Nashville
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Menerima pesertaFase 2
- Nashville General Hospital, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Menerima pesertaFase 1/2
- Tennessee Oncology, PLLC, Nashville
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Research Site, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Sites, Nashville
- Clinical Study Site, Nashville
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Menerima pesertaFase 1/2
- Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Menerima pesertaFase 2/3
- Local Institution - 007-928-B, Nashville
- Tennessee Oncology - Nashville - Centennial Clinic - Medical Oncology, Nashville
- Local Institution - 007-928-K, Nashville
- dan 6 lainnya
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Menerima pesertaFase 2
- Sarah Cannon Research Institute, Nashville
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Menerima pesertaFase 1
- Sarah Cannon and HCA Research Institute, Nashville
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Menerima pesertaFase 1/2
- SCRI Oncology Partners, Nashville
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Tennessee Oncology, Nashville
- USO - US Oncology Research Network, Nashville
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- Tennessee Oncology, Nashville
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Menerima pesertaFase 1/2
- SCRI Oncology Partners - PPDS, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Menerima pesertaFase 1/2
- Tennessee Oncology, Nashville
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Menerima pesertaFase 1
- Vanderbilt - Ingram Cancer Center, Nashville
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Menerima pesertaFase 1
- Vanderbilt University, Nashville
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium), Nashville
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Tennessee Oncology - Nashville St. Thomas Midtown Clinic, Nashville
- Tennessee Oncology Nashville - SCRI Oncology Partners, Nashville
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
- USO - US Oncology Research Network, Nashville
- Vanderbilt University School of Medicine, Nashville
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
Menerima pesertaStudi observasional
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Vanderbilt University Medical Center, Nashville
SMP-3124LP in Adults With Advanced Solid Tumors
Menerima pesertaFase 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, LLC, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Menerima pesertaFase 1/2
- Tennessee Oncology, Nashville
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute Oncology Partners, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Menerima pesertaFase 1
- Tennessee Oncology, Nashville
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Menerima pesertaFase 3
- Tennessee Oncology, Nashville
- Vanderbilt - Ingram Cancer Center, Nashville
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Menerima pesertaFase 1
- Scri Oncology Partners, Nashville
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Menerima pesertaFase 3
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Menerima pesertaFase 1
- US Oncology Research LLC, Nashville
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Menerima pesertaFase 1/2
- Tennessee Oncology, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
Study of XB010 in Subjects With Solid Tumors
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Menerima pesertaFase 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Menerima pesertaFase 1
- Research Site, Nashville
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Menerima pesertaFase 1
- SCRI - Oncology Partners, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Menerima pesertaFase 1
- Vanderbilt University Medical Center, Nashville
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Menerima pesertaFase 1/2
- SCRI Oncology Partners, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Research Site, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Menerima peserta
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Menerima pesertaFase 1/2
- SCRI Oncology Partners, Nashville
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Tennessee Oncology, PLLC, Nashville
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Nashville
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute Oncology Partners, Nashville
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Menerima pesertaFase 1/2
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Menerima pesertaFase 1/2
- Vanderbilt University/Ingram Cancer Center, Nashville
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
- Seattle, WA53 studi
Studi lain di Nashville
- Kanker Payudara81 studi
- Kanker Metastatik70 studi
- Kanker Kolorektal69 studi
- Kanker (semua jenis)65 studi
- Kanker Ovarium49 studi
- Kanker Prostat43 studi
- Kanker Paru40 studi
- Karsinoma Sel Skuamosa Kepala dan Leher39 studi
- Kanker Pankreas39 studi
- Kanker Endometrium38 studi
- Melanoma33 studi
- Mieloma Multipel32 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.